Aging is often linked to a decline in associative memory. Prior research has shown that older adults have difficulty retrieving specific associative memory but can retrieve gist associative memory when deliberately differentiating test pairs with different levels of specificity during associative recognition. In this study, we utilized the context reinstatement paradigm to examine whether older adults could retrieve specific memory in situations where associations do not necessarily need to be voluntarily retrieved. Thirty-five older adults were directed to intentionally link objects with unique background scenes during encoding. Subsequently, test objects were presented against either the reinstated or similar background scenes during a recognition memory task, where participants were required to identify whether the objects were old or new regardless of their background contexts. Event-related potentials (ERP) were recorded to uncover the electrophysiological correlates of specific associative episodic memory. Behavioral results revealed higher memory sensitivity for object recognition when the background scenes were reinstated than when those were similar in older adults. ERP results indicated that older adults exhibited a more prominent fronto-centrally distributed positivity during object recognition in the reinstated than in similar contexts. Our results suggest that older adults may preserve their ability to retrieve specific memory for associations through an involuntary, spontaneous recollection process, which holds important theoretical implications for age-related associative memory deficits.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuropsychologia.2024.109014 | DOI Listing |
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Addiction and Mental Health, Toronto, ON, Canada.
Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.
Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!